Compare FXNC & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FXNC | SABS |
|---|---|---|
| Founded | 1907 | 2014 |
| Country | United States | United States |
| Employees | 308 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 258.1M | 293.9M |
| IPO Year | 2012 | 2020 |
| Metric | FXNC | SABS |
|---|---|---|
| Price | $28.75 | $2.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $33.00 | $11.64 |
| AVG Volume (30 Days) | 12.7K | ★ 684.9K |
| Earning Date | 10-23-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.63% | N/A |
| EPS Growth | ★ 96.00 | 78.53 |
| EPS | ★ 1.93 | N/A |
| Revenue | ★ $7,717,000.00 | N/A |
| Revenue This Year | $7.52 | N/A |
| Revenue Next Year | $4.62 | N/A |
| P/E Ratio | $15.02 | ★ N/A |
| Revenue Growth | ★ 7.40 | N/A |
| 52 Week Low | $23.71 | $2.44 |
| 52 Week High | $33.24 | $5.15 |
| Indicator | FXNC | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 37.27 | 43.62 |
| Support Level | $28.80 | $2.44 |
| Resistance Level | $30.57 | $4.03 |
| Average True Range (ATR) | 0.89 | 0.26 |
| MACD | -0.19 | -0.02 |
| Stochastic Oscillator | 16.91 | 37.58 |
First National Corp is a bank holding company of First Bank, which is a commercial bank. Its core offering includes loans, deposits, wealth management, and other products and services. The Company operates through two reportable operating segments: Community Banking and wealth management. The Community Banking segment involves making loans and generating deposits from individuals, businesses, and charitable organizations. Wealth Management Services offers corporate trustee services, trust and estate administration, IRA administration and custody services. The company has revenue from Community Banking segment.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.